TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells

BMC Cancer

Lionel Flamant³  Edith Roegiers³  Michael Pierre²  Aurélie Hayez¹  Christiane Sterpin¹  Olivier De Backer¹  Thierry Arnould³  Yves Poumay¹  Carine Michiels³ 

[1] URPhyM-NARILIS, University of Namur-FUNDP, 61 rue de Bruxelles, 5000, Namur, Belgium

[2] Molecular Biology Research Unit (URBM)-NARILIS, University of Namur-FUNDP, 61 rue de Bruxelles, 5000, Namur, Belgium

[3] URBC-NARILIS, University of Namur-FUNDP, 61 rue de Bruxelles, 5000, Namur, Belgium

关键词: Microarrays;    Apoptosis;    Hypoxia;    Gene expression;    Cancer;    Chemoresistance;   

Others  :  1080217
DOI  :  10.1186/1471-2407-12-391

 received in 2012-01-12, accepted in 2012-08-31,  发布年份 2012

【 摘 要 】

Background

Hypoxia is a common characteristic of solid tumors associated with reduced response to radio- and chemotherapy, therefore increasing the probability of tumor recurrence. The aim of this study was to identify new mechanisms responsible for hypoxia-induced resistance in breast cancer cells.

Methods

MDA-MB-231 and HepG2 cells were incubated in the presence of taxol or etoposide respectively under normoxia and hypoxia and apoptosis was analysed. A whole transcriptome analysis was performed in order to identify genes whose expression profile was correlated with apoptosis. The effect of gene invalidation using siRNA was studied on drug-induced apoptosis.

Results

MDA-MB-231 cells incubated in the presence of taxol were protected from apoptosis and cell death by hypoxia. We demonstrated that TMEM45A expression was associated with taxol resistance. TMEM45A expression was increased both in MDA-MB-231 human breast cancer cells and in HepG2 human hepatoma cells in conditions where protection of cells against apoptosis induced by chemotherapeutic agents was observed, i.e. under hypoxia in the presence of taxol or etoposide. Moreover, this resistance was suppressed by siRNA-mediated silencing of TMEM45A. Kaplan Meier curve showed an association between high TMEM45A expression and poor prognostic in breast cancer patients. Finally, TMEM45 is highly expressed in normal differentiated keratinocytes both in vitro and in vivo, suggesting that this protein is involved in epithelial functions.

Conclusion

Altogether, our results unravel a new mechanism for taxol and etoposide resistance mediated by TMEM45A. High levels of TMEM45A expression in tumors may be indicative of potential resistance to cancer therapy, making TMEM45A an interesting biomarker for resistance.

【 授权许可】

   
2012 Flamant et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Farrell A: A close look at cancer. Nat Med 2011, 17(3):262-265.
• [2]Michael M, Doherty MM: Tumoral drug metabolism: overview and its implications for cancer therapy. J Clin Oncol 2005, 23(1):205-229.
• [3]Gillet JP, Efferth T, Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007, 1775(2):237-262.
• [4]Lage H: An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65(20):3145-3167.
• [5]Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev 2006, 5(3):219-234.
• [6]Blagosklonny MV: Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 2005, 4(12):1693-1698.
• [7]Cosse JP, Michiels C: Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008, 8(7):790-797.
• [8]Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G: HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 2010, 316(12):1985-1993.
• [9]Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, et al.: Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82(10):699-757.
• [10]Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 12(19–20):853-859.
• [11]Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
• [12]Milani M, Harris AL: Targeting tumour hypoxia in breast cancer. Eur J Cancer 2008, 44(18):2766-2773.
• [13]Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002, 8(6):1831-1837.
• [14]Helczynska K, Larsson AM, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K: Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 2008, 68(22):9212-9220.
• [15]Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F: GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011, 26(10):1279-1286.
• [16]Wu XZ, Xie GR, Chen D: Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22(8):1178-1182.
• [17]Jensen RL: Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009, 92(3):317-335.
• [18]Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA, Workman P: Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994, 29(3):427-431.
• [19]Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, et al.: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24.
• [20]Hockel M, Schlenger K, Hockel S, Vaupel P: Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999, 59(18):4525-4528.
• [21]Seeber LM, Zweemer RP, Verheijen RH, van Diest PJ: Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int 2010, 2010:580971.
• [22]Yasuda H, Kaneta T, Takai Y, Nakayama K, Iwata R, Ito M, Tsujitani M, Takahashi S, Yamada S, Sasaki T, et al.: Tumor hypoxia imaging with [F-18] fluoronitroimidazole in non-small-cell lung cancer. J Am Geriatr Soc 2007, 55(7):1142-1144.
• [23]Ruan K, Song G, Ouyang G: Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009, 107(6):1053-1062.
• [24]Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M, Michiels C: Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer 2007, 6:61.
• [25]Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C: Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia 2009, 11(10):976-986.
• [26]Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR: Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 1999, 25(5):279-291.
• [27]Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88(11):2619-2628.
• [28]Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A: The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev 2009, 35(8):662-667.
• [29]Ozkan A, Fiskin K: Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol 2004, 56(4):435-444.
• [30]Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL: The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 2002, 277(19):16547-16552.
• [31]Flamant L, Notte A, Ninane N, Raes M, Michiels C: Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 2010, 9:191. BioMed Central Full Text
• [32]Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J, Michiels C: Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 2008, 7:27.
• [33]Sullivan R, Graham CH: Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 2009, 8(6):1702-1713.
• [34]Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ: An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009, 37(14):4587-4602.
• [35]Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-679.
• [36]Atanasova G, Jans R, Zhelev N, Mitev V, Poumay Y: Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. Biochem Pharmacol 2005, 70(6):824-836.
• [37]Minner F, Herphelin F, Poumay Y: Study of epidermal differentiation in human keratinocytes cultured in autocrine conditions. Methods Mol Biol 2010, 585:71-82.
• [38]Rezvani HR, Ali N, Nissen LJ, Harfouche G, de Verneuil H, Taieb A, Mazurier F: HIF-1alpha in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol 2011, 131(9):1793-1805.
• [39]Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB: The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005, 8(6):443-454.
• [40]Weinmann M, Belka C, Guner D, Goecke B, Muller I, Bamberg M, Jendrossek V: Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. Oncogene 2005, 24(38):5914-5922.
• [41]Jean JC, Rich CB, Joyce-Brady M: Hypoxia results in an HIF-1-dependent induction of brain-specific aldolase C in lung epithelial cells. Am J Physiol 2006, 291(5):L950-L956.
• [42]Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H: Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett 2004, 576(1–2):14-20.
• [43]Kim JW, Tchernyshyov I, Semenza GL, Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3(3):177-185.
• [44]Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M, Ivashchenko Y: Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 2001, 8(4):367-376.
• [45]Cangul H: Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet 2004, 5:27.
• [46]Martin-Rendon E, Hale SJ, Ryan D, Baban D, Forde SP, Roubelakis M, Sweeney D, Moukayed M, Harris AL, Davies K, et al.: Transcriptional profiling of human cord blood CD133+ and cultured bone marrow mesenchymal stem cells in response to hypoxia. Stem Cells 2007, 25(4):1003-1012.
• [47]Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J: Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002, 277(8):6183-6187.
• [48]Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, Buhrer C: Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008, 372(4):892-897.
• [49]Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, D'Orazi G: Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget 2011, 2(12):1191-1202.
• [50]Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T: RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008, 14(9):939-948.
• [51]Liu JL, Wang Y, Jiang J, Kong R, Yang YM, Ji HF, Shi YZ: Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA. Chin Med J 2010, 123(20):2901-2907.
• [52]Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S: Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res 2010, 30(7):2531-2538.
• [53]Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM: Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol 2010, 225(3):822-828.
• [54]Verma A, Mehta K: Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Resist Updat 2007, 10(4–5):144-151.
• [55]Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM, Bae HC, Kim TW, Lee SH, Choi Y, et al.: Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010, 29(3):356-367.
• [56]Shen DW, Gottesman MM: RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res 2012, 29(3):643-650.
• [57]Mathay C, Giltaire S, Minner F, Bera E, Herin M, Poumay Y: Heparin-binding EGF-like growth factor is induced by disruption of lipid rafts and oxidative stress in keratinocytes and participates in the epidermal response to cutaneous wounds. J Invest Dermatol 2008, 128(3):717-727.
• [58]Pierre M, DeHertogh B, Gaigneaux A, DeMeulder B, Berger F, Bareke E, Michiels C, Depiereux E: Meta-analysis of archived DNA microarrays identifies genes regulated by hypoxia and involved in a metastatic phenotype in cancer cells. BMC Cancer 2010, 10:176. BioMed Central Full Text
• [59]Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004, 99(468):9.
• [60]Liu H, Zeeberg BR, Qu G, Koru AG, Ferrucci A, Kahn A, Ryan MC, Nuhanovic A, Munson PJ, Reinhold WC, et al.: AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics 2007, 23(18):2385-2390.